Exploring The Role Of MiRSNPs In Diagnosis And Prognosis Of Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$428,065.00
Summary
Genetic variants, when used alongside PSA and family history, could be a better early biomarker to identify men predisposable to develop prostate cancer or/and to distinguish slowly progressive from aggressive disease. We will undertake a comprehensive study on a special class of genetic variants "miRSNPs" in the non-coding region of the prostate cancer related genes and will also identify their mechanism of action, and their potential as a biomarker for prostate cancer diagnosis and prognosis.
I am a clinician-scientist and endocrinologist most interested in clinical problems associated with bone, in particular the highly heritable disease of osteoporosis. I hope by studying genetic determinants of bone mass to determine the key genes involved, with the long term aim of informing the development of novel therapies for this common, painful and disabling disease.